Sector Focus


Caliber has successfully planned with both venture backed private development stage companies and publicly traded biopharmaceutical companies. We understand the unique challenges of emerging companies as well as global biotech organizations and we have developed a keen sense of what it takes to discover and develop biologically derived treatments to enhance the quality of care in markets with substantially under met medical needs.


Poseida Therapeutics

Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need. We have demonstrated proof-of-principle that validates the potential of our differentiated genome engineering technologies and their therapeutic applications. Our technology platforms have broad applicability and Poseida's long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases. The initial applications of Poseida's technologies will be in gene therapy and CAR-T product candidates for liver disorders and cancer, respectively.

Search Projects